Polyclonal secondary FGFR2 mutations drive acquired resistance to FGFR inhibition in patients with FGFR2 fusion–positive cholangiocarcinoma. Goyal, L., Saha, S. K, Liu, L. Y, Siravegna, G., Leshchiner, I., Ahronian, L. G, Lennerz, J. K, Vu, P., Deshpande, V., Kambadakone, A., & others Cancer discovery, 7(3):252–263, American Association for Cancer Research, 2017.
bibtex   
@article{goyal2017polyclonal,
  title={Polyclonal secondary FGFR2 mutations drive acquired resistance to FGFR inhibition in patients with FGFR2 fusion--positive cholangiocarcinoma},
  author={Goyal, Lipika and Saha, Supriya K and Liu, Leah Y and Siravegna, Giulia and Leshchiner, Ignaty and Ahronian, Leanne G and Lennerz, Jochen K and Vu, Phuong and Deshpande, Vikram and Kambadakone, Avinash and others},
  journal={Cancer discovery},
  volume={7},
  number={3},
  pages={252--263},
  year={2017},
  publisher={American Association for Cancer Research}
}

Downloads: 0